New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)

Kiyoko Umene, Kouji Banno, Iori Kisu, Megumi Yanokura, Yuya Nogami, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Eiichirou Tominaga, Nobuyuki Susumu, Daisuke Aoki

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)


Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, the development of new therapy is required from the perspectives of conservation of fertility and efficacy for recurrent and intractable cancer. New candidate therapeutic agents for endometrial cancer include fourth-generation progestins for inhibition of growth and differentiation of endometrial glands; metformin for reduction of hTERT expression in the endometrium and inhibition of the mTOR pathway by activation of AMPK, with consequent inhibition of the cell cycle; mTOR inhibitors for supressing growth of cancer cells by G1 cell cycle arrest; microRNAs involved in the molecular mechanisms of oncogenesis and progression; and HDAC inhibitors that block the growth of cancer cells by transcriptional elevation of tumor-suppressor genes, cell cycle arrest and induction of apoptosis. In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer.

Original languageEnglish
Pages (from-to)855-860
Number of pages6
JournalOncology reports
Issue number3
Publication statusPublished - 2013 Mar


  • Endometrial cancer
  • Fourth-generation progestins
  • MTOR inhibitors
  • Metformin
  • MicroRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)'. Together they form a unique fingerprint.

Cite this